Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel therapy for asthma.

S A Bryan1, M J Leckie, T T Hansel

  • 1National Heart and Lung Institute, Royal Brompton Clinical Studies Unit, Imperial College, London, UK.

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of granulocyte pharmacodynamics in whole blood by flow cytometry.

Methods in molecular medicine·2011
Same author

Automated quantitation of peripheral blood neutrophil activation in patients with myocardial ischaemia.

International journal of cardiology·2004
Same author

Sputum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+ CD103+).

Thorax·2003
Same author

Biological treatments for systemic lupus erythematosus.

Scandinavian journal of rheumatology·2002
Same author

Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis.

Rheumatology (Oxford, England)·2002
Same author

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Lancet (London, England)·2001
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Asthma treatment is advancing with novel therapies targeting inflammation and severe cases. Future developments aim for disease-modifying immunotherapy to alter asthma

Area of Science:

  • Pulmonology
  • Pharmacology
  • Immunology

Background:

  • Global asthma burden is rising, necessitating new therapeutic strategies.
  • Current asthma treatments offer palliative care but require daily administration.
  • Limited development of novel asthma therapeutics in recent decades.

Purpose of the Study:

  • To review current and emerging asthma therapies.
  • To highlight the need for improved treatments for severe and acute asthma.
  • To discuss the potential of disease-modifying immunotherapy.

Main Methods:

  • Review of existing literature on asthma therapeutics.
  • Analysis of ongoing clinical development for asthma medications.
  • Discussion of novel targets for asthma treatment.

Related Experiment Videos

Main Results:

  • Numerous therapies targeting inflammation (eosinophils, IgE, cytokines) are in development.
  • New agents are needed for severe asthma unresponsive to corticosteroids.
  • Novel treatments are expected to be introduced soon.

Conclusions:

  • Understanding asthma mechanisms is crucial for therapeutic advancement.
  • Future asthma therapies will likely include targeted anti-inflammatory agents.
  • Disease-modifying immunotherapy represents a long-term goal for asthma management.